Skip to main content
. Author manuscript; available in PMC: 2013 Jan 25.
Published in final edited form as: Lancet. 2011 Mar 28;377(9773):1276–1287. doi: 10.1016/S0140-6736(10)62349-5

Table 2. Clinical development of novel osteoporosis therapies.

Drug Target Function Class Phase Route
Anti-resorptives
Denosumab* RANK ligand Stem cell factor for osteoclasts Antibody against RANKL 3 (completed) SC
Odanacatib Cathepsin K Osteoclastic enzyme that degrades collagens Cathepsin K inhibitor 3 PO
Saracatinib c-src kinase Enzyme involved in osteoclast activation c-src inhibitor 2 PO
Anabolic
MK-5442 Calcium-sensing receptor Triggers PTH release if inhibited Calcilytic agent 2 PO
AMG 785 Sclerostin Inhibitor of the Wnt/β-catenin pathway Antibody against sclerostin 2 SC
BHQ 880 Dickkopf-1 Inhibitor of the Wnt/β-catenin pathway Antibody against dickkopf-1 1/2 SC
*

Approved in Europe and the US in May/June, 2010.

Abbreviations: SC, subcutaneous, PO, per os.